Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15420110 | 1.00 | RORC (0.36) | RORCBTKEPHX1CTSKNFKB1 | |
| SCHEMBL26253780 | 1.00 | RORC (0.36) | RORCBTKEPHX1CTSKNFKB1 | |
| SCHEMBL26253864 | 0.89 | CTSK (0.36) | RORCBTKEPHX1CTSKNFKB1 | |
| SCHEMBL20063805 | 0.84 | BTK (0.40) | RORCBTKCTSKNFKB1NFKB2 | |
| SCHEMBL20095940 | 0.84 | BTK (0.40) | RORCBTKCTSKNFKB1NFKB2 | |
| SCHEMBL26253688 | 0.84 | BTK (0.36) | RORCBTKEPHX1CTSKNFKB1 | |
| SCHEMBL26253683 | 0.84 | BTK (0.36) | RORCBTKEPHX1CTSKNFKB1 | |
| SCHEMBL15420199 | 0.81 | BTK (0.47) | RORCBTKCTSKNFKB1NFKB2 | |
| SCHEMBL20959100 | 0.81 | BTK (0.47) | RORCBTKCTSKNFKB1NFKB2 | |
| SCHEMBL12989321 | 0.81 | BTK (0.47) | RORCBTKCTSKNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | RORC 1197/4885BTK 774/4885EPHX1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.